10.76

0.09% -0.010

Pre-market: 10.76

Maplight Therapeutics Inc (MPLT)

Overview News Price History Discussions Forecast

Maplight Therapeutics Inc stock is traded at $10.76, with a volume of 341.81K. It is down -0.09% in the last 24 hours and down -5.28% over the past month. MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.

Previous Close:

$10.77

Open:

$10.6

24h Volume:

341.81K

Relative Volume:

0.40

Market Cap:

$597.99M

Revenue:

Net Income/Loss:

$-161.15M

P/E Ratio:

-2.8964

EPS:

-3.7149

Net Cash Flow:

$-138.61M

1W Performance:

-4.95%

1M Performance:

-5.28%

6M Performance:

-36.63%

1Y Performance:

+0.00%

1-Day Range:

$10.16

$10.86

1-Week Range:

$10.13

$11.28

52-Week Range:

$9.10

$40.43

Maplight Therapeutics Inc Stock (MPLT) Company Profile

Name

Maplight Therapeutics Inc

Sector

Healthcare (1068)

Industry

Biotechnology (595)

Phone

650-839-4360

Address

800 CHESAPEAKE DRIVE, REDWOOD CITY

Employee

133

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

MPLT's Discussions on Twitter

Compare MPLT vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MPLT Maplight Therapeutics Inc	10.76	597.99M	0	-161.15M	-138.61M	-3.7149
VRTX Vertex Pharmaceuticals Inc	522.38	132.40B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	796.02	81.95B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	194.82	77.78B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	962.22	60.20B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	199.86	42.84B	742.00K	-1.37B	-1.07B	-7.0731

Maplight Therapeutics Inc Stock (MPLT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-08-26	Initiated	Needham	Buy
Apr-07-26	Initiated	TD Cowen	Buy
Mar-19-26	Initiated	Canaccord Genuity	Buy
Nov-21-25	Initiated	Jefferies	Buy
Nov-21-25	Initiated	Leerink Partners	Outperform
Nov-21-25	Initiated	Morgan Stanley	Overweight
Nov-21-25	Initiated	Stifel	Buy

View All

Maplight Therapeutics Inc Stock (MPLT) Latest News

Sep 23, 2026

MPLT Stock Plunges 73% — Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose - Stocktwits

Sep 23, 2026

Sep 20, 2026

MapLight Therapeutics, Inc.(NasdaqGS:MPLT) dropped from S&P Biotechnology Select Industry Index - marketscreener.com

Sep 20, 2026

Sep 19, 2026

IPO Databook: MapLight Therapeutics (MPLT US)Sep 2026 - Smartkarma

Sep 19, 2026

Sep 18, 2026

MapLight Therapeutics (MPLT) General Counsel Kristopher Hanson Sells 16,509 Shares - GuruFocus

Sep 18, 2026

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Sep 18, 2026

Sep 16, 2026

MapLight Therapeutics (MPLT) exec to sell shares under preset trading plan - Stock Titan

Sep 16, 2026

MapLight Therapeutics (MPLT) Edges Lower to $11.85, Testing Support Near $11.26Long Term Entry Picks - dars.gov.et

Sep 16, 2026

Sep 15, 2026

Maplight Therapeutics (NASDAQ:MPLT) Stock Price Down 7.8%Here's Why - MarketBeat

Sep 15, 2026

Sep 11, 2026